RecruitingPhase 1NCT07038005

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SPGL008 Monotherapy for Patients With Advanced Malignant Tumors

Sponsor

Shenyang Sunshine Pharmaceutical Co., LTD.

Enrollment

96 participants

Start Date

Jul 30, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Malignant Tumors

Summary

This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SPGL008 for people with advanced malignant tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.